| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 46 | 2022 | 2553 | 2.560 |
Why?
|
| Colorectal Neoplasms | 14 | 2022 | 981 | 1.720 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2014 | 317 | 1.230 |
Why?
|
| Antibodies, Monoclonal | 11 | 2017 | 1402 | 1.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 21 | 2021 | 967 | 0.910 |
Why?
|
| Bevacizumab | 19 | 2022 | 289 | 0.830 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2021 | 157 | 0.790 |
Why?
|
| Disease-Free Survival | 22 | 2022 | 1214 | 0.720 |
Why?
|
| Lung Neoplasms | 12 | 2014 | 2347 | 0.720 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2014 | 1114 | 0.660 |
Why?
|
| Fluorouracil | 24 | 2022 | 561 | 0.620 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2022 | 1096 | 0.540 |
Why?
|
| Leucovorin | 15 | 2022 | 224 | 0.520 |
Why?
|
| Neoplasm Metastasis | 15 | 2017 | 1108 | 0.520 |
Why?
|
| Indazoles | 2 | 2012 | 67 | 0.510 |
Why?
|
| Aged | 53 | 2019 | 19119 | 0.510 |
Why?
|
| Imidazoles | 2 | 2012 | 148 | 0.500 |
Why?
|
| Middle Aged | 61 | 2022 | 25910 | 0.490 |
Why?
|
| Pancreatic Neoplasms | 7 | 2019 | 669 | 0.480 |
Why?
|
| Maximum Tolerated Dose | 10 | 2019 | 272 | 0.470 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 25 | 0.450 |
Why?
|
| Paclitaxel | 8 | 2019 | 479 | 0.450 |
Why?
|
| Carcinoma, Large Cell | 2 | 2011 | 39 | 0.450 |
Why?
|
| Head and Neck Neoplasms | 12 | 2022 | 1063 | 0.440 |
Why?
|
| Registries | 2 | 2016 | 780 | 0.430 |
Why?
|
| Aged, 80 and over | 25 | 2019 | 6794 | 0.400 |
Why?
|
| Survival Rate | 15 | 2019 | 1890 | 0.390 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2014 | 423 | 0.380 |
Why?
|
| Treatment Outcome | 21 | 2019 | 8217 | 0.380 |
Why?
|
| Indoles | 7 | 2014 | 312 | 0.370 |
Why?
|
| Pyrroles | 6 | 2014 | 187 | 0.370 |
Why?
|
| Adult | 45 | 2019 | 26542 | 0.350 |
Why?
|
| Female | 59 | 2022 | 46078 | 0.340 |
Why?
|
| Male | 53 | 2022 | 42309 | 0.340 |
Why?
|
| Liver Neoplasms | 3 | 2019 | 754 | 0.330 |
Why?
|
| Deoxycytidine | 7 | 2019 | 238 | 0.330 |
Why?
|
| Carcinoma, Lobular | 1 | 2009 | 81 | 0.330 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2009 | 158 | 0.310 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2019 | 111 | 0.310 |
Why?
|
| Adenocarcinoma | 7 | 2011 | 1194 | 0.310 |
Why?
|
| Glucuronosyltransferase | 2 | 2019 | 186 | 0.300 |
Why?
|
| Salvage Therapy | 2 | 2019 | 235 | 0.300 |
Why?
|
| Humans | 70 | 2022 | 89157 | 0.290 |
Why?
|
| Colonic Neoplasms | 4 | 2022 | 573 | 0.290 |
Why?
|
| ErbB Receptors | 7 | 2014 | 500 | 0.290 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 329 | 0.280 |
Why?
|
| Antineoplastic Agents | 10 | 2022 | 2412 | 0.280 |
Why?
|
| Organoplatinum Compounds | 7 | 2017 | 97 | 0.270 |
Why?
|
| Disease Progression | 10 | 2018 | 1488 | 0.260 |
Why?
|
| Camptothecin | 5 | 2022 | 193 | 0.260 |
Why?
|
| Quinazolines | 4 | 2012 | 221 | 0.260 |
Why?
|
| Prognosis | 11 | 2019 | 3776 | 0.250 |
Why?
|
| Carboplatin | 5 | 2012 | 304 | 0.230 |
Why?
|
| Breast Neoplasms | 7 | 2014 | 3003 | 0.230 |
Why?
|
| Cohort Studies | 7 | 2014 | 2864 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2018 | 1363 | 0.220 |
Why?
|
| Quinolines | 2 | 2019 | 91 | 0.190 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 127 | 0.190 |
Why?
|
| Neoplasm Staging | 12 | 2015 | 2002 | 0.190 |
Why?
|
| Pyrazoles | 2 | 2019 | 150 | 0.190 |
Why?
|
| Intestinal Perforation | 2 | 2012 | 36 | 0.180 |
Why?
|
| Prospective Studies | 7 | 2022 | 4281 | 0.180 |
Why?
|
| Cisplatin | 11 | 2012 | 617 | 0.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2018 | 261 | 0.170 |
Why?
|
| Thromboembolism | 2 | 2010 | 120 | 0.160 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2019 | 45 | 0.160 |
Why?
|
| Sulfonamides | 4 | 2021 | 318 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2012 | 604 | 0.150 |
Why?
|
| Androstenes | 1 | 2018 | 45 | 0.150 |
Why?
|
| Food | 1 | 2018 | 89 | 0.150 |
Why?
|
| Pyridines | 2 | 2019 | 315 | 0.150 |
Why?
|
| Survival Analysis | 6 | 2019 | 1534 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 285 | 0.140 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 96 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 112 | 0.140 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 121 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2019 | 1940 | 0.140 |
Why?
|
| Young Adult | 5 | 2016 | 6294 | 0.130 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 824 | 0.130 |
Why?
|
| Proportional Hazards Models | 4 | 2014 | 848 | 0.130 |
Why?
|
| Anilides | 1 | 2015 | 48 | 0.130 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 390 | 0.130 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 100 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 860 | 0.120 |
Why?
|
| Drug Administration Schedule | 6 | 2019 | 895 | 0.120 |
Why?
|
| Biomarkers, Tumor | 6 | 2019 | 1547 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 329 | 0.120 |
Why?
|
| Methotrexate | 6 | 1992 | 250 | 0.120 |
Why?
|
| Hypertension | 2 | 2010 | 744 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2019 | 551 | 0.120 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 3 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3660 | 0.110 |
Why?
|
| Neoplasms | 4 | 2014 | 3037 | 0.110 |
Why?
|
| Exanthema | 1 | 2014 | 39 | 0.110 |
Why?
|
| Blood Proteins | 1 | 2014 | 146 | 0.110 |
Why?
|
| Pilot Projects | 4 | 2017 | 868 | 0.110 |
Why?
|
| Proteomics | 1 | 2014 | 230 | 0.100 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 20 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 599 | 0.100 |
Why?
|
| Adolescent | 10 | 2014 | 9243 | 0.090 |
Why?
|
| Time Factors | 6 | 2014 | 5331 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 175 | 0.090 |
Why?
|
| Combined Modality Therapy | 7 | 2008 | 1710 | 0.090 |
Why?
|
| Bendamustine Hydrochloride | 2 | 2021 | 11 | 0.090 |
Why?
|
| Alkaline Phosphatase | 1 | 2010 | 132 | 0.090 |
Why?
|
| Statistics as Topic | 1 | 2011 | 234 | 0.090 |
Why?
|
| Diabetes Complications | 2 | 2010 | 170 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2012 | 834 | 0.090 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1991 | 170 | 0.090 |
Why?
|
| Lymphoma | 1 | 1991 | 265 | 0.090 |
Why?
|
| Rituximab | 2 | 2021 | 119 | 0.090 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2021 | 89 | 0.090 |
Why?
|
| Tissue Distribution | 1 | 2009 | 293 | 0.080 |
Why?
|
| Safety | 1 | 2010 | 149 | 0.080 |
Why?
|
| Everolimus | 2 | 2022 | 40 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2018 | 3376 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2019 | 1715 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2009 | 502 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2009 | 200 | 0.080 |
Why?
|
| Skin Diseases | 1 | 2009 | 173 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2011 | 1768 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2009 | 280 | 0.070 |
Why?
|
| Carcinoma | 1 | 2010 | 443 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2011 | 410 | 0.070 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2006 | 41 | 0.070 |
Why?
|
| Taxoids | 3 | 2012 | 130 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 988 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 3 | 2018 | 359 | 0.070 |
Why?
|
| Erlotinib Hydrochloride | 3 | 2011 | 90 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2006 | 102 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2004 | 38 | 0.060 |
Why?
|
| Prednisone | 2 | 2018 | 259 | 0.060 |
Why?
|
| Amifostine | 1 | 2004 | 51 | 0.060 |
Why?
|
| Drug Eruptions | 1 | 2004 | 34 | 0.060 |
Why?
|
| Radiation-Protective Agents | 1 | 2004 | 98 | 0.060 |
Why?
|
| Thionucleotides | 1 | 2004 | 56 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 133 | 0.060 |
Why?
|
| Capecitabine | 2 | 2014 | 98 | 0.050 |
Why?
|
| Sex Factors | 2 | 2019 | 1063 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 196 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 616 | 0.050 |
Why?
|
| Age Factors | 2 | 2019 | 1867 | 0.050 |
Why?
|
| Remission Induction | 6 | 2008 | 740 | 0.050 |
Why?
|
| Genotype | 2 | 2019 | 1848 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2006 | 781 | 0.040 |
Why?
|
| Etoposide | 3 | 2008 | 198 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2013 | 1070 | 0.040 |
Why?
|
| Stomach Neoplasms | 2 | 2019 | 281 | 0.040 |
Why?
|
| Albumins | 1 | 2019 | 129 | 0.040 |
Why?
|
| Azetidines | 1 | 2019 | 37 | 0.040 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2018 | 6 | 0.040 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2019 | 33 | 0.040 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 114 | 0.040 |
Why?
|
| United States | 4 | 2018 | 6965 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2022 | 688 | 0.040 |
Why?
|
| Singapore | 1 | 2018 | 16 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 1999 | 84 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 214 | 0.040 |
Why?
|
| Dehydroepiandrosterone | 1 | 2018 | 49 | 0.040 |
Why?
|
| Piperidines | 1 | 2019 | 165 | 0.040 |
Why?
|
| Filgrastim | 1 | 2017 | 57 | 0.040 |
Why?
|
| Fasting | 1 | 2018 | 163 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1998 | 91 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 217 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 321 | 0.030 |
Why?
|
| Testosterone | 1 | 2018 | 275 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 229 | 0.030 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 1996 | 20 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 385 | 0.030 |
Why?
|
| Technetium | 1 | 1995 | 29 | 0.030 |
Why?
|
| Radioimmunodetection | 1 | 1995 | 13 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 40 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 485 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2018 | 358 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 358 | 0.030 |
Why?
|
| Drug Therapy, Combination | 5 | 2011 | 783 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 396 | 0.030 |
Why?
|
| Interferon-alpha | 4 | 1998 | 226 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1995 | 83 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 1995 | 106 | 0.030 |
Why?
|
| Neuropilin-2 | 1 | 2014 | 2 | 0.030 |
Why?
|
| Neuropilin-1 | 1 | 2014 | 14 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2014 | 76 | 0.030 |
Why?
|
| Trastuzumab | 1 | 2014 | 71 | 0.030 |
Why?
|
| Glutamates | 1 | 2014 | 89 | 0.030 |
Why?
|
| Recombinant Proteins | 4 | 1998 | 1012 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 684 | 0.030 |
Why?
|
| Cetuximab | 1 | 2014 | 117 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2013 | 162 | 0.030 |
Why?
|
| Anemia, Sideroblastic | 1 | 1993 | 7 | 0.030 |
Why?
|
| Inflammation | 1 | 2019 | 971 | 0.030 |
Why?
|
| Guanine | 1 | 2014 | 207 | 0.030 |
Why?
|
| Sirolimus | 1 | 2014 | 170 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 244 | 0.030 |
Why?
|
| Zinc | 1 | 1993 | 93 | 0.030 |
Why?
|
| Fatigue | 1 | 2013 | 179 | 0.030 |
Why?
|
| Risk Factors | 2 | 2014 | 5483 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 2 | 2005 | 184 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2009 | 590 | 0.020 |
Why?
|
| Chromosomal Instability | 1 | 2011 | 19 | 0.020 |
Why?
|
| Ploidies | 1 | 2011 | 41 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2302 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2011 | 86 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 71 | 0.020 |
Why?
|
| ras Proteins | 1 | 2011 | 130 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 164 | 0.020 |
Why?
|
| Semaphorins | 1 | 2009 | 17 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 504 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 1424 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2009 | 50 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1720 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 181 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 975 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 85 | 0.020 |
Why?
|
| Mutation | 2 | 2011 | 4137 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 1993 | 414 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2008 | 134 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2014 | 2011 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 529 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 780 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 451 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 354 | 0.020 |
Why?
|
| Piperazines | 1 | 2009 | 283 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 1999 | 470 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 665 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 922 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1763 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 374 | 0.020 |
Why?
|
| Hydroxyurea | 2 | 1998 | 239 | 0.020 |
Why?
|
| Ketoconazole | 1 | 2006 | 26 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 645 | 0.020 |
Why?
|
| Bleomycin | 2 | 1990 | 102 | 0.020 |
Why?
|
| Mitoxantrone | 1 | 2006 | 68 | 0.020 |
Why?
|
| Receptors, Estrogen | 3 | 1983 | 393 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2009 | 1296 | 0.020 |
Why?
|
| Vincristine | 2 | 1983 | 112 | 0.020 |
Why?
|
| Erythema Multiforme | 1 | 2004 | 4 | 0.020 |
Why?
|
| Blister | 1 | 2004 | 8 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 9022 | 0.020 |
Why?
|
| Quality of Life | 1 | 2013 | 1665 | 0.020 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2004 | 22 | 0.020 |
Why?
|
| Radiometry | 1 | 2004 | 56 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 68 | 0.010 |
Why?
|
| Stereoisomerism | 2 | 1996 | 102 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1837 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1875 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 11743 | 0.010 |
Why?
|
| Melphalan | 1 | 1981 | 98 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 2004 | 1150 | 0.010 |
Why?
|
| Ascites | 1 | 1981 | 56 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 2614 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 1593 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2658 | 0.010 |
Why?
|
| Levoleucovorin | 1 | 1998 | 3 | 0.010 |
Why?
|
| Pleural Neoplasms | 1 | 1981 | 198 | 0.010 |
Why?
|
| Femoral Nerve | 1 | 1998 | 8 | 0.010 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 1998 | 19 | 0.010 |
Why?
|
| Acute Kidney Injury | 1 | 1982 | 312 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1998 | 299 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2004 | 3721 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1999 | 682 | 0.010 |
Why?
|
| Tetrahydrofolates | 1 | 1996 | 13 | 0.010 |
Why?
|
| Gallium Radioisotopes | 1 | 1995 | 31 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 27330 | 0.010 |
Why?
|
| Patient Selection | 1 | 1999 | 684 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1995 | 332 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1993 | 79 | 0.010 |
Why?
|
| Child | 1 | 2004 | 7154 | 0.010 |
Why?
|
| Iron | 1 | 1993 | 168 | 0.010 |
Why?
|
| Cyclophosphamide | 2 | 1983 | 299 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1992 | 138 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1993 | 168 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1993 | 445 | 0.010 |
Why?
|
| Probability | 2 | 1982 | 353 | 0.010 |
Why?
|
| Doxorubicin | 2 | 1983 | 298 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1990 | 434 | 0.010 |
Why?
|
| Pyrimidines | 1 | 1992 | 373 | 0.010 |
Why?
|
| Tamoxifen | 1 | 1983 | 168 | 0.000 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1981 | 40 | 0.000 |
Why?
|
| Menopause | 1 | 1982 | 76 | 0.000 |
Why?
|
| Magnesium | 1 | 1982 | 178 | 0.000 |
Why?
|
| Axilla | 1 | 1982 | 104 | 0.000 |
Why?
|
| Amino Acids | 1 | 1982 | 245 | 0.000 |
Why?
|
| Lymph Node Excision | 1 | 1983 | 220 | 0.000 |
Why?
|
| Pleural Effusion | 1 | 1981 | 47 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1983 | 331 | 0.000 |
Why?
|
| Mastectomy | 1 | 1983 | 245 | 0.000 |
Why?
|
| Mitomycins | 1 | 1979 | 13 | 0.000 |
Why?
|
| Fever | 1 | 1981 | 128 | 0.000 |
Why?
|
| Remission, Spontaneous | 1 | 1979 | 53 | 0.000 |
Why?
|
| Calcium | 1 | 1982 | 1174 | 0.000 |
Why?
|